Soya & peanut protein allergy. Discontinue use if persisting severe diarrhoea, nausea & vomiting occur; GI perforation develops. Patients w/ inherited predisposition to bleeding or receiving full dose anticoagulative treatment; low body wt (<65 kg); recent history of MI or stroke; higher CV risk eg, known CAD, acute myocardial ischemia; thromboembolic events; previous abdominal surgery, recent history of hollow organ perforation, history of peptic ulceration, diverticular disease; HTN; QTc prolongation. May impair wound healing. Asian & female patients. Monitor hepatic transaminase & bilirubin levels prior to, during 1st 3 mth & periodically thereafter. Concomitant use w/ corticosteroids, NSAIDs. Co-administration w/ pirfenidone. May affect ability to drive & use machines. Mild hepatic impairment. Not recommended in patients w/ moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic & severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception during & at least 3 mth after last dose. Not to be used during pregnancy & lactation. Childn 0-18 yr. Elderly ≥75 yr.